The news outlook is brightening in the short term!
Biotechs with positive news are currently shining with relative strength. CureVac, following the EPO ruling and the presentation of the Q1 report, is among these stocks!
Reading Time: 1 minute
Recently, it has been observed that biotechs with positive news have once again gained favor among speculative investors. This trend has also been evident with CureVac. On May 15, the European Patent Office (EPO) confirmed the validity of CureVac's patent EP 4 023 755 B1 in a modified form. The opposition filed against this patent by BioNTech SE, Pfizer Inc., and other parties in December 2023 was largely rejected. As a result, investors have once again identified CureVac as a potential turnaround candidate. On May 20, the company was also able...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
